
### [MONDO:0000612](http://purl.obolibrary.org/obo/MONDO_0000612)
**Label:** lymphatic system cancer

**Subclasses:** [MONDO:0017599](http://purl.obolibrary.org/obo/MONDO_0017599) (splenic diffuse red pulp small b-cell lymphoma), [MONDO:0000715](http://purl.obolibrary.org/obo/MONDO_0000715) (lymph node adenoid cystic carcinoma), [MONDO:0001607](http://purl.obolibrary.org/obo/MONDO_0001607) (intrapelvic lymph node leukemic reticuloendotheliosis), [MONDO:0003209](http://purl.obolibrary.org/obo/MONDO_0003209) (thymus adenocarcinoma), [MONDO:0004638](http://purl.obolibrary.org/obo/MONDO_0004638) (lymphosarcoma), [MONDO:0009975](http://purl.obolibrary.org/obo/MONDO_0009975) (reticulum cell sarcoma), [MONDO:0020323](http://purl.obolibrary.org/obo/MONDO_0020323) (primary mediastinal large b-cell lymphoma), [MONDO:0000951](http://purl.obolibrary.org/obo/MONDO_0000951) (thymus lymphoma), [MONDO:0005966](http://purl.obolibrary.org/obo/MONDO_0005966) (spleen cancer), [MONDO:0006119](http://purl.obolibrary.org/obo/MONDO_0006119) (breast mucosa-associated lymphoid tissue lymphoma), [MONDO:0002376](http://purl.obolibrary.org/obo/MONDO_0002376) (spleen angiosarcoma), [MONDO:0003047](http://purl.obolibrary.org/obo/MONDO_0003047) (thymus large cell carcinoma), [MONDO:0006455](http://purl.obolibrary.org/obo/MONDO_0006455) (thymic undifferentiated carcinoma), [MONDO:0002592](http://purl.obolibrary.org/obo/MONDO_0002592) (invasive malignant thymoma), [MONDO:0004475](http://purl.obolibrary.org/obo/MONDO_0004475) (thymus clear cell carcinoma), [MONDO:0003086](http://purl.obolibrary.org/obo/MONDO_0003086) (thymus mucoepidermoid carcinoma), [MONDO:0006452](http://purl.obolibrary.org/obo/MONDO_0006452) (thymic sarcomatoid carcinoma), [MONDO:0004297](http://purl.obolibrary.org/obo/MONDO_0004297) (lymphoepithelioma-like thymic carcinoma), [MONDO:0006451](http://purl.obolibrary.org/obo/MONDO_0006451) (thymic carcinoma), [MONDO:0001082](http://purl.obolibrary.org/obo/MONDO_0001082) (lymph node cancer), [MONDO:0004092](http://purl.obolibrary.org/obo/MONDO_0004092) (thymus basaloid carcinoma), [MONDO:0019465](http://purl.obolibrary.org/obo/MONDO_0019465) (Nodal marginal zone b-cell lymphoma), [MONDO:0001614](http://purl.obolibrary.org/obo/MONDO_0001614) (intra-abdominal lymph node mast cell malignancy), [MONDO:0002966](http://purl.obolibrary.org/obo/MONDO_0002966) (splenic manifestation of prolymphocytic leukemia), [MONDO:0004528](http://purl.obolibrary.org/obo/MONDO_0004528) (lymph node palisaded myofibroblastoma), [MONDO:0019462](http://purl.obolibrary.org/obo/MONDO_0019462) (splenic marginal zone lymphoma), [MONDO:0003534](http://purl.obolibrary.org/obo/MONDO_0003534) (papillary thymic adenocarcinoma), [MONDO:0005438](http://purl.obolibrary.org/obo/MONDO_0005438) (metastatic malignant neoplasm in the lymph nodes), [MONDO:0004107](http://purl.obolibrary.org/obo/MONDO_0004107) (splenic manifestation of leukemia), [MONDO:0004104](http://purl.obolibrary.org/obo/MONDO_0004104) (splenic manifestation of hairy cell leukemia), [MONDO:0006226](http://purl.obolibrary.org/obo/MONDO_0006226) (gastric mucosa-associated lymphoid tissue lymphoma), [MONDO:0002586](http://purl.obolibrary.org/obo/MONDO_0002586) (thymus cancer), [MONDO:0004122](http://purl.obolibrary.org/obo/MONDO_0004122) (thymus small cell carcinoma), [MONDO:0003551](http://purl.obolibrary.org/obo/MONDO_0003551) (thymus adenosquamous carcinoma), [MONDO:0006420](http://purl.obolibrary.org/obo/MONDO_0006420) (small intestinal mucosa-associated lymphoid tissue lymphoma), [MONDO:0006464](http://purl.obolibrary.org/obo/MONDO_0006464) (thyroid gland mucosa-associated lymphoid tissue lymphoma), [MONDO:0003493](http://purl.obolibrary.org/obo/MONDO_0003493) (thymus squamous cell carcinoma), [MONDO:0007650](http://purl.obolibrary.org/obo/MONDO_0007650) (MALT lymphoma), [MONDO:0017604](http://purl.obolibrary.org/obo/MONDO_0017604) (marginal zone lymphoma), [MONDO:0010017](http://purl.obolibrary.org/obo/MONDO_0010017) (sea-blue histiocyte syndrome), 

**Mapped go classes:** [GO:0034372](http://purl.obolibrary.org/obo/GO_0034372) (very-low-density lipoprotein particle remodeling), [GO:0032374](http://purl.obolibrary.org/obo/GO_0032374) (regulation of cholesterol transport), [GO:0060228](http://purl.obolibrary.org/obo/GO_0060228) (phosphatidylcholine-sterol O-acyltransferase activator activity), [GO:0008289](http://purl.obolibrary.org/obo/GO_0008289) (lipid binding), [GO:0042157](http://purl.obolibrary.org/obo/GO_0042157) (lipoprotein metabolic process), [GO:0005576](http://purl.obolibrary.org/obo/GO_0005576) (extracellular region), [GO:0051092](http://purl.obolibrary.org/obo/GO_0051092) (positive regulation of NF-kappaB transcription factor activity), [GO:0042632](http://purl.obolibrary.org/obo/GO_0042632) (cholesterol homeostasis), [GO:0042159](http://purl.obolibrary.org/obo/GO_0042159) (lipoprotein catabolic process), [GO:0005874](http://purl.obolibrary.org/obo/GO_0005874) (microtubule), [GO:0043524](http://purl.obolibrary.org/obo/GO_0043524) (negative regulation of neuron apoptotic process), [GO:0032449](http://purl.obolibrary.org/obo/GO_0032449) (CBM complex), [GO:0005769](http://purl.obolibrary.org/obo/GO_0005769) (early endosome), [GO:0050750](http://purl.obolibrary.org/obo/GO_0050750) (low-density lipoprotein particle receptor binding), [GO:0043691](http://purl.obolibrary.org/obo/GO_0043691) (reverse cholesterol transport), [GO:0051000](http://purl.obolibrary.org/obo/GO_0051000) (positive regulation of nitric-oxide synthase activity), [GO:0006915](http://purl.obolibrary.org/obo/GO_0006915) (apoptotic process), [GO:0072562](http://purl.obolibrary.org/obo/GO_0072562) (blood microparticle), [GO:0017127](http://purl.obolibrary.org/obo/GO_0017127) (cholesterol transporter activity), [GO:0010873](http://purl.obolibrary.org/obo/GO_0010873) (positive regulation of cholesterol esterification), [GO:0070326](http://purl.obolibrary.org/obo/GO_0070326) (very-low-density lipoprotein particle receptor binding), [GO:0042627](http://purl.obolibrary.org/obo/GO_0042627) (chylomicron), [GO:0034380](http://purl.obolibrary.org/obo/GO_0034380) (high-density lipoprotein particle assembly), [GO:0015485](http://purl.obolibrary.org/obo/GO_0015485) (cholesterol binding), [GO:0034364](http://purl.obolibrary.org/obo/GO_0034364) (high-density lipoprotein particle), [GO:0034363](http://purl.obolibrary.org/obo/GO_0034363) (intermediate-density lipoprotein particle), [GO:1900221](http://purl.obolibrary.org/obo/GO_1900221) (regulation of amyloid-beta clearance), [GO:0006695](http://purl.obolibrary.org/obo/GO_0006695) (cholesterol biosynthetic process), [GO:0042981](http://purl.obolibrary.org/obo/GO_0042981) (regulation of apoptotic process), [GO:0042101](http://purl.obolibrary.org/obo/GO_0042101) (T cell receptor complex), [GO:0005543](http://purl.obolibrary.org/obo/GO_0005543) (phospholipid binding), [GO:0006810](http://purl.obolibrary.org/obo/GO_0006810) (transport), [GO:0001540](http://purl.obolibrary.org/obo/GO_0001540) (amyloid-beta binding), [GO:0046889](http://purl.obolibrary.org/obo/GO_0046889) (positive regulation of lipid biosynthetic process), [GO:0006869](http://purl.obolibrary.org/obo/GO_0006869) (lipid transport), [GO:0030516](http://purl.obolibrary.org/obo/GO_0030516) (regulation of axon extension), [GO:0006707](http://purl.obolibrary.org/obo/GO_0006707) (cholesterol catabolic process), [GO:0005737](http://purl.obolibrary.org/obo/GO_0005737) (cytoplasm), [GO:0046696](http://purl.obolibrary.org/obo/GO_0046696) (lipopolysaccharide receptor complex), [GO:0031102](http://purl.obolibrary.org/obo/GO_0031102) (neuron projection regeneration), [GO:0033344](http://purl.obolibrary.org/obo/GO_0033344) (cholesterol efflux), [GO:0019433](http://purl.obolibrary.org/obo/GO_0019433) (triglyceride catabolic process), [GO:0106003](http://purl.obolibrary.org/obo/GO_0106003) (amyloid-beta complex), [GO:0033700](http://purl.obolibrary.org/obo/GO_0033700) (phospholipid efflux), 

**Class expressions from DL-Learner:**

- Thing 52.79%
- [GO:0034363](http://purl.obolibrary.org/obo/GO_0034363) (intermediate-density lipoprotein particle) 52.63%
- [GO:0034385](http://purl.obolibrary.org/obo/GO_0034385) (triglyceride-rich plasma lipoprotein particle) 37.99%
- [GO:0034385](http://purl.obolibrary.org/obo/GO_0034385) (triglyceride-rich plasma lipoprotein particle) and ([GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component) or [GO:0007337](http://purl.obolibrary.org/obo/GO_0007337) (obsolete unilateral process)) 37.99%
- [GO:0034385](http://purl.obolibrary.org/obo/GO_0034385) (triglyceride-rich plasma lipoprotein particle) and ([GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component) or [GO:0007336](http://purl.obolibrary.org/obo/GO_0007336) (obsolete bilateral process)) 37.99%
- [GO:0034385](http://purl.obolibrary.org/obo/GO_0034385) (triglyceride-rich plasma lipoprotein particle) and ([GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component) or [GO:0007335](http://purl.obolibrary.org/obo/GO_0007335) (null)) 37.99%
- [GO:0034385](http://purl.obolibrary.org/obo/GO_0034385) (triglyceride-rich plasma lipoprotein particle) and ([GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component) or [GO:0007334](http://purl.obolibrary.org/obo/GO_0007334) (null)) 37.99%
- [GO:0034385](http://purl.obolibrary.org/obo/GO_0034385) (triglyceride-rich plasma lipoprotein particle) and ([GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component) or [GO:0007333](http://purl.obolibrary.org/obo/GO_0007333) (null)) 37.99%
- [GO:0034385](http://purl.obolibrary.org/obo/GO_0034385) (triglyceride-rich plasma lipoprotein particle) and ([GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component) or [GO:0007332](http://purl.obolibrary.org/obo/GO_0007332) (null)) 37.99%
- [GO:0034385](http://purl.obolibrary.org/obo/GO_0034385) (triglyceride-rich plasma lipoprotein particle) and ([GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component) or [GO:0007331](http://purl.obolibrary.org/obo/GO_0007331) (null)) 37.99%
- [GO:0034385](http://purl.obolibrary.org/obo/GO_0034385) (triglyceride-rich plasma lipoprotein particle) and ([GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component) or [GO:0007330](http://purl.obolibrary.org/obo/GO_0007330) (null)) 37.99%
- [GO:0034385](http://purl.obolibrary.org/obo/GO_0034385) (triglyceride-rich plasma lipoprotein particle) and ([GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component) or [GO:0007328](http://purl.obolibrary.org/obo/GO_0007328) (null)) 37.99%
- [GO:0034385](http://purl.obolibrary.org/obo/GO_0034385) (triglyceride-rich plasma lipoprotein particle) and ([GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component) or [GO:0007327](http://purl.obolibrary.org/obo/GO_0007327) (null)) 37.99%
- [GO:0034385](http://purl.obolibrary.org/obo/GO_0034385) (triglyceride-rich plasma lipoprotein particle) and ([GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component) or [GO:0007326](http://purl.obolibrary.org/obo/GO_0007326) (null)) 37.99%
- [GO:0034385](http://purl.obolibrary.org/obo/GO_0034385) (triglyceride-rich plasma lipoprotein particle) and ([GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component) or [GO:0007325](http://purl.obolibrary.org/obo/GO_0007325) (null)) 37.99%


